ArticleFrontiers in sleep2025
Novel active-feedback device improves sleep quality in insomnia disorder: a randomized placebo-controlled trial.
Article in Frontiers in sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acoustic stimulation and other emerging approaches to enhance sleep: design notes for the next generation of closed-loop neurostimulation technology.Frontiers in neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Insomnia disorder is a public health challenge associated with impaired cognitive functioning, reduced quality of life, and adverse mental health outcomes. This study examined the effectiveness of SleepCogni, an active-feedback device, in reducing insomnia symptom severity and improving perceived sleep quality in individuals with insomnia disorder. Method: A two-arm, parallel-group trial design was used, with 80 participants randomized to either the experimental group or the placebo control group. Participants provided self-reported measures of insomnia severity, sleep continuity, and user experience as main outcome variables. Results: Repeated measures analysis of variance showed that participants in the experimental group reported significantly greater improvements in insomnia symptom severity than the control group (Time × Treatment). Although the mean difference did not reach the threshold for clinical significance, 37.5% of the participants achieved this threshold within 1 week of treatment. Mixed-effects models showed significant improvements in sleep efficiency and total sleep time, based on sleep diary records. Finally, an independent samples Conclusion: The SleepCogni device appears to be a useful tool for improving sleep outcomes in individuals with insomnia disorder, showing effects on both insomnia severity and subjectively evaluated sleep. The SleepCogni device presents a useful intervention that might be used alone or as a complement to increase the effectiveness of existing treatments, such as cognitive behavioral therapy for insomnia. Clinical trial registration: https://osf.io/rswcb, identifier: osf-registrations-rswcb-v1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.